Schunk, M., Le, L., Syunyaeva, Z., Haberland, B., Tänzler, S., Mansmann, U., Schwarzkopf, L., Seidl, H., Streitwieser, S., Hofmann, M., Müller, T., Weiss, T., Morawietz, P., Rehfuess, E., Huber, R. M., Berger, U., Bausewein, C.

Effectiveness of a specialised breathlessness service for patients with advanced disease in Germany: a pragmatic fast track randomised controlled trial (BreathEase)


European Respiratory Journal. doi: 10.1183/13993003.02139-2020


Breathlessness is a common and distressing symptom in advanced stages of malignant and non-malignant disease [1–4]. Breathlessness is highly prevalent, occurring in up to 80% of patients with advanced cancer, in around 56–98% of patients with chronic obstructive pulmonary disease (COPD) and in up to 90% of patients with chronic heart failure (CHF) [5, 6]. Patients with chronic breathlessness resulting from advanced disease report high symptom burden, palliative care needs [7–9] and suffer from anxiety and depression [10]. Negative consequences on health and quality of life (QoL) have been shown, e.g. for COPD patients [11]. Breathlessness is one of the most common reasons for emergency department visits and hospital admissions in cancer patients [12–14].


IFT Institut für Therapieforschung
Leopoldstraße 175
80804 München

Tel. +49 89 360804-0
Fax +49 89 360804-19